Alpharma Shares Lower
Biogen Idec (BIIB ) posted a fourth quarter loss of $4.03 per share, vs. earnings per share of 26 cents (GAAP basis one year earlier, despite sharply higher revenues. The biotech company cited the writeoff of acquired in-process R&D related to its merger with Idec. It reaffirmed its long-term goal of achieving a 15% compounded annual growth rate. It also set a 12 million share buyback program.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.